196 results on '"Andrews, Miles C."'
Search Results
2. UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma
3. Immune-related adverse events secondary to immunotherapy in oncology: A guide for general practice
4. Gut microbiota – a double-edged sword in cancer immunotherapy
5. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
6. Multi-modal molecular programs regulate melanoma cell state
7. Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study
8. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
9. Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
10. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
11. Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.
12. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
13. Predictors of Response to Immune Checkpoint Blockade
14. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
15. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
16. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma
17. Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
18. Figures S1-S9 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
19. Supplementary Tables 1-3 from Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma
20. Supplementary Figure 3 from Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma
21. Supplementary information from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
22. Supplementary Figure 1 from Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma
23. Supplementary Table S2 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
24. Data from Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma
25. Supplementary Figure 2 from Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma
26. Design, optimisation and standardisation of a high‐dimensional spectral flow cytometry workflow assessing T‐cell immunophenotype in patients with melanoma
27. Interaction between Targeted Therapy and Immunotherapy
28. Predictors of Response to Immune Checkpoint Blockade
29. Immune-related adverse events secondary to immunotherapy in oncology.
30. Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
31. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
32. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
33. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
34. Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
35. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma
36. Adrenocorticotropic hormone, blood pressure, and serum erythropoietin concentrations in the rat
37. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
38. Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors
39. Abstract 3776: Spatially resolved immunogenomic analyses reveal diverse sub tumoral microenvironments in the context of melanoma immunotherapy
40. Abstract 2357: Identification of microRNAs associated with melanoma immunity and immunotherapy outcome
41. A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases
42. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
43. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
44. Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy
45. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
46. The good, the (not so) bad and the ugly of immune homeostasis in melanoma
47. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
48. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
49. Abstract CT156: Novel neoadjuvant targeted therapy trial yields insight into molecular mechanisms of response
50. PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.